Publication List 2021

1984-94, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022

12
（482）		 Ozawa T, Miyazono K, Morikawa M.
Preparation of monovalent follistatin-like 3-Fc-fusion protein and evaluation of its effects on muscle mass in mice.
STAR Protoc. 2021 Dec 17;2(4):100839.
11
（481）		 Fukuda T, Fukuda R, Koinuma D, Moustakas A, Miyazono K, Heldin CH.
BMP2-induction of FN14 promotes protumorigenic signaling in gynecologic cancer cells.
Cell Signal. 2021 Sep 10;87:110146.
10
（480）		 Fukuda T, Fukuda R, Miyazono K, Heldin CH.
Tumor Promoting Effect of BMP Signaling in Endometrial Cancer.
Int J Mol Sci. 2021 Jul 23;22(15):7882.
9
（479）		 Takahashi K, Tanabe R, Ehata S, Kubota SI, Morishita Y, Ueda HR, Miyazono K.
Visualization of the cancer cell cycle by tissue-clearing technology using the Fucci reporter system.
Cancer Sci. 2021 Sep;112(9):3796-3809.
8
（478）		 Momoi Y, Nishida J, Miyakuni K, Kuroda M, Kubota SI, Miyazono K, Ehata S.
Heterogenous expression of Endoglin marks advanced renal cancer with distinct tumor microenvironment fitness.
Cancer Sci. 2021 Aug;112(8):3136-3149.
7
（477）		 Ozawa T, Morikawa M, Morishita Y, Ogikubo K, Itoh F, Koinuma D, Nygren PÅ, Miyazono K.
Systemic administration of monovalent follistatin-like 3-Fc-fusion protein increases muscle mass in mice.
iScience. 2021 May 14;24(5):102488.
6
（476）		 Motizuki M, Koinuma D, Yokoyama T, Itoh Y, Omata C, Miyazono K, Saitoh M, Miyazawa K.
TGF-β-induced cell motility requires downregulation of ARHGAPs to sustain Rac1 activity.
J Biol Chem. Jan-Jun 2021;296:100545.
5
（475）		 Kubota SI, Takahashi K, Mano T, Matsumoto K, Katsumata T, Shi S, Tainaka K, Ueda HR, Ehata S, Miyazono K.
Whole-organ analysis of TGF-β-mediated remodelling of the tumour microenvironment by tissue clearing.
Commun Biol. 2021 Mar 5;4(1):294.
4
（474）		 Yamamoto H, Sakai N, Ohte S, Sato T, Sekimata K, Matsumoto T, Nakamura K, Watanabe H, Mishima-Tsumagari C, Tanaka A, Hashizume Y, Honma T, Katagiri T, Miyazono K, Tomoda H, Shirouzu M, Koyama H.
Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
Bioorg Med Chem Lett. 2021 Apr 15;38:127858.
3
（473）		 Kok SY, Oshima H, Takahashi K, Nakayama M, Murakami K, Ueda HR, Miyazono K, Oshima M.
Malignant subclone drives metastasis of genetically and phenotypically heterogenous cell clusters through fibrotic niche generation.
Nat Commun. 2021 Feb 8;12(1):863.
2
（472）		 Tamura Y, Morikawa M, Tanabe R, Miyazono K, Koinuma D.
Anti-pyroptotic function of TGF-β is suppressed by a synthetic dsRNA analogue in triple negative breast cancer cells.
Mol Oncol. 2021 May;15(5):1289-1307.
1
（471）		 Takahashi K, Ehata S, Miyauchi K, Morishita Y, Miyazawa K, Miyazono K.
Neurotensin receptor 1 signaling promotes pancreatic cancer progression.
Mol Oncol. 2021 Jan;15(1):151-166.